Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
PRESENTATION · Nov 2024 · PDF
BBIO - Acoramidis - ACC 2024 - CMR Imaging Substudy from ATTRibute-CM Phase 3 Study
PRESENTATION · Dec 2023 · PDF
Acoramidis - AHA 2023 - Clinical Outcome Improvements
PRESENTATION · Dec 2023 · PDF
Infigratinib - ESPE 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
PRESENTATION · Dec 2023 · PDF
ADH1 - ASHG 2023 Novel Variants of the CaSR
PRESENTATION · Dec 2023 · PDF
BBP-418 - WMS 2023 - Phase 2 Data at 21 Months; Ambulatory Improvements at 9 Months
PRESENTATION · Dec 2023 · PDF
Canavan GTx BBP-812 - Neurology for Science 2023 - CANaspire Phase 1/2 Study
PRESENTATION · Dec 2023 · PDF
Acoramidis - October 2023 - 4 Year Update from OLE Phase 2 Study
PRESENTATION · Dec 2023 · PDF
Infigratinib - ENDO 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
PRESENTATION · Dec 2023 · PDF